Suppliers / Rising

Rising

United States 319 employees Updated 9 July 2026

Rising is an API and finished-dose manufacturer based in United States. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with US FDA and DMP (NO). Its most recent recorded inspection, by US FDA, closed on 8 April 2022 as VAI.

2
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
606
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 8 April 2022 VAI US FDA
  • 16 May 2018 OAI US FDA
  • 9 December 2016 NAI US FDA
  • 10 June 2016 OAI US FDA
  • 6 June 2014 VAI US FDA
  • 3 May 2013 OAI US FDA
  • 26 October 2012 VAI US FDA
  • 25 May 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Coimbra, Portugal Not on file
Decatur, United States 1419498

What they file, and where

Molecule Regulators Docs
Colestipol US FDA 1
Metaxalone US FDA 1

Also appears on these molecule pages

Abiraterone finished dose Anagrelide finished dose Azathioprine finished dose Benazepril finished dose Benzoyl Peroxide finished dose Bisoprolol finished dose Bumetanide finished dose Buspirone finished dose Calcitriol finished dose Captopril finished dose Cefixime finished dose Chlorothiazide finished dose
Show 62 more molecule pages
Chlorzoxazone finished dose Clomipramine finished dose Clotrimazole finished dose Colestipol API Cromoglicic Acid finished dose Dalfampridine finished dose Dipyridamole finished dose Doxazosin finished dose Doxepin finished dose Doxercalciferol finished dose Enalapril finished dose Entacapone finished dose Eplerenone finished dose Eptifibatide finished dose Etomidate finished dose Fingolimod finished dose Fluocinolone Acetonide finished dose Fluphenazine finished dose Gatifloxacin finished dose Indapamide finished dose Itraconazole finished dose Lansoprazole finished dose Latanoprost finished dose Levocarnitine finished dose Levodopa finished dose Lorazepam finished dose Meclizine finished dose Memantine finished dose Meprobamate finished dose Mesalamine finished dose Mesalazine finished dose Mesna finished dose Metaxalone API Methylphenidate finished dose Mexiletine finished dose Montelukast finished dose Nadolol finished dose Nateglinide finished dose Nitazoxanide finished dose Nitrofurantoin finished dose Ofloxacin finished dose Olopatadine finished dose Phenytoin finished dose Propafenone finished dose Pyridostigmine finished dose Ranitidine finished dose Rasagiline finished dose Sevelamer finished dose Sirolimus finished dose Sotalol finished dose Spironolactone finished dose Sulindac finished dose Sumatriptan finished dose Temozolomide finished dose Testosterone Cypionate finished dose Tinidazole finished dose Tolterodine finished dose Tramadol finished dose Trazodone finished dose Triethylenetetramine finished dose Zileuton finished dose Zonisamide finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 604 None
DMP (NO) 2 None

Comparing suppliers?

Choose your molecules and target markets. Rising comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 99 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 8 April 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability